Anne De Groot, MD

Education


MD (1983) Pritzker School of Medicine, University of Chicago

BA (1978) Smith College

Affiliation


Medical Director, Clinica Esperanza (Hope Clinic)

Co-founder and CEO/CSO, EpiVax

Research Interest

Dr. De Groot is board certified in Internal Medicine and Infectious Diseases. She is the volunteer Medical Director and currently practices Internal Medicine at the Clinica Esperanza (Hope Clinic), a free clinic for residents who do not have health insurance. Prior to EpiVax, she was a professor at Brown University, where she established the TB/HIV Research Lab. The laboratory attracted a range of intelligent and creative Brown University undergraduate and graduate students who worked with Dr. De Groot on projects ranging from improving healthcare for inmates living in correctional facilities in the United States, improving access to care in West Africa, and developing cutting edge tools for analyzing protein sequences and designing vaccines.

While at Brown University, she worked with colleagues to develop the EpiMer and EpiMatrix epitope mapping tools. These were among the first motif-based and matrix-based, fully automated T cell epitope mapping tools. The team applied these tools to HIV vaccine design and were soon travelling to HIV Vaccine conferences as a group to demonstrate how the tools could be used to help design vaccines that would be effective against a range of HIV strains. Additional tools were developed that automated genome sequence analysis for highly conserved, immunogenic epitopes, starting from any protein sequence.

Recent Publications

Richard G, Princiotta MF, Bridon D, Martin WD, Steinberg GD, De Groot AS. Neoantigen-based personalized cancer vaccines: the emergence of precision cancer immunotherapy. Expert Rev Vaccines. 2022 Feb;21(2):173-184. doi: 10.1080/14760584.2022.2012456. Epub 2021 Dec 19. PMID: 34882038.

Giorgetti SI, Etcheverrigaray M, Terry F, Martin W, De Groot AS, Ceaglio N, Oggero M, Mufarrege EF. Development of highly stable and de-immunized versions of recombinant alpha interferon: Promising candidates for the treatment of chronic and emerging viral diseases. Clin Immunol. 2021 Dec;233:108888. doi: 10.1016/j.clim.2021.108888. Epub 2021 Nov 17. PMID: 34798238; PMCID: PMC8595249.

Winterling K, Martin WD, De Groot AS, Daufenbach J, Kistner S, Schüttrumpf J. Development of a novel fully functional coagulation factor VIII with reduced immunogenicity utilizing an in silico prediction and deimmunization approach. J Thromb Haemost. 2021 Sep;19(9):2161-2170. doi: 10.1111/jth.15413. Epub 2021 Jun 30. PMID: 34060724; PMCID: PMC8456792.

Kotraiah V, Phares TW, Terry FE, Hindocha P, Silk SE, Nielsen CM, Moise L, Tucker KD, Ashfield R, Martin WD, De Groot AS, Draper SJ, Gutierrez GM, Noe AR. Identification and Immune Assessment of T Cell Epitopes in Five Plasmodium falciparum Blood Stage Antigens to Facilitate Vaccine Candidate Selection and Optimization. Front Immunol. 2021 Jul 7;12:690348. doi: 10.3389/fimmu.2021.690348. PMID: 34305923; PMCID: PMC8294059.

De Groot AS, Desai AK, Lelias S, Miah SMS, Terry FE, Khan S, Li C, Yi JS, Ardito M, Martin WD, Kishnani PS. Immune Tolerance-Adjusted Personalized Immunogenicity Prediction for Pompe Disease. Front Immunol. 2021 Jun 16;12:636731. doi: 10.3389/fimmu.2021.636731. PMID: 34220802; PMCID: PMC8242953.

Noe AR, Terry FE, Schanen BC, Sassano E, Hindocha P, Phares TW, Moise L, Christen JM, Tucker KD, Kotraiah V, Drake DR 3rd, Martin WD, De Groot AS, Gutierrez GM. Bridging Computational Vaccinology and Vaccine Development Through Systematic Identification, Characterization, and Downselection of Conserved and Variable Circumsporozoite Protein CD4 T Cell Epitopes From Diverse Plasmodium falciparum Strains. Front Immunol. 2021 Jun 8;12:689920. doi: 10.3389/fimmu.2021.689920. PMID: 34168657; PMCID: PMC8217813.

McCarthy M, Barry K, Estrada C, Veliz B, Rosales D, Leonard M, De Groot AS. Recruitment, Training, and Roles of the Bilingual, Bicultural Navegantes: Developing a Specialized Workforce of Community Health Workers to Serve a Low- Income, Spanish-Speaking Population in Rhode Island. Front Public Health. 2021 Jun 4;9:666566. doi: 10.3389/fpubh.2021.666566. PMID: 34150707; PMCID: PMC8213204.

PubMed

Complete List of Published Work in PUBMED

Coming soon.

Coming soon.